Comparative efficacy of proton pump inhibitors VS. H2 receptor antagonists in the treatment of gastroesophageal reflux disease
Abstract
Gastroesophageal reflux disease (GERD) is a common condition characterized by acid reflux into the esophagus, leading to symptoms such as heartburn and regurgitation. Objective: To compare the efficacy of Proton Pump Inhibitors (PPIs) and H2 Receptor Antagonists (H2RAs) in treating GERD in a cohort of 800 patients, assessing symptom relief, healing rates, and side effects. Methods: A total of 800 patients diagnosed with GERD were added to receive either PPIs (n=400) or H2RAs (n=400) for a treatment period of 8 weeks. The primary outcome was improved GERD symptoms, measured using a standardized GERD symptom questionnaire. Results: The study found that the PPI group demonstrated a significantly higher improvement in symptom relief, with 78% achieving complete symptom resolution compared to 54% in the H2RA group (p < 0.05). Esophageal healing rates were also superior in the PPI group, with 84% showing complete healing compared to 62% in the H2RA group. Furthermore, the time to symptom relief was shorter in the PPI group (average of 5 days) compared to the H2RA group (8 days). Adverse effects were minimal and comparable between the two groups, with mild headaches (8% vs. 6%) and gastrointestinal discomfort (10% vs. 9%) being the most frequently reported. Conclusion: Proton Pump Inhibitors are more effective than H2 Receptor Antagonists in relieving symptoms, accelerating symptom resolution, and promoting esophageal healing in patients with GERD. Although both treatments are…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 800 participants or records.
Read the paper
Related studies
- Advantages and Disadvantages of Long-term Proton Pump Inhibitor Use
- Ivth brazilian consensus conference on helicobacter pylori infection
- A pSMAD/CDX2 complex is essential for the intestinalization of epithelial metaplasia
- S2k-Leitlinie Gastroösophageale Refluxkrankheit und eosinophile Ösophagitis der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) – März 2023 – AWMF-Registernummer: 021–013
- Step-by-step management of refractory gastresophageal reflux disease
- Insights into Effects/Risks of Chronic Hypergastrinemia and Lifelong PPI Treatment in Man Based on Studies of Patients with Zollinger–Ellison Syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.